biotech semaglutide Novo Nordisk's Ozempic excels in diabetes, kidney disease trial Semaglutide may Improve Metabolic Control

Tyruko (natalizumab) was launched in the US in November 2025 as the first and only multiple-sclerosis biosimilar, approved for all indications of the reference medicine

If were going to treat obesity as a chronic disease, we need coverage that reflects that

These three nutrients work together to target problem areas and pack a powerful fat-blasting punch

Relative EPO deficiency is further evidenced by studies showing blunted EPO responses to anemia in CKD patients, where serum EPO levels fail to rise adequately in proportion to hemoglobin decline (Artunc and Risler, 2007)

BPC-157 injections can be split between levels if needed, though the total daily dose should remain within standard protocol ranges

2018, Roomi et al